| 1 min read
Register for free to listen to this article
Listen with Speechify
0:00
1:00
COPENHAGEN, Denmark—Novozymes Biopharma DK A/S, a subsidiary of Novozymes A/S, a world leader in bioinnovation, has announced that its albumin-based VELTIS half-life extension technology is being used by GlaxoSmithKline in the recently authorized Eperzan (albiglutide) for the treatment of type 2 diabetes in Europe.
 
The application of Novozymes’ VELTIS technology in the drug delivers an extended half-life which will enable patients to inject only once per week.
 
"The first approval for a product based on Novozymes' VELTIS technology, and marketed by one of the largest pharmaceutical companies in the world,  marks a significant milestone for our half-life extension platform", says Thomas Videbæk, Executive Vice President, Business Development, Novozymes. “We consider this authorization real proof that VELTIS can offer true benefits to patients, reducing the inconvenience with daily drug dosing."
 
VELTIS technology is a series of native and engineered human albumins. When combined with a drug candidate, it offers the potential for tunable control of therapeutic half-life in a manner previously unachievable with other half-life extension platforms. In particular, the technology opens the door towards weekly, bi-weekly, or even monthly dosing regimens, a monumental shift away from the daily dosing regimens currently necessary to manage medical conditions.
 
SOURCE: Novozymes

About the Author

Related Topics

Loading Next Article...
Loading Next Article...
Subscribe to Newsletter

Subscribe to our eNewsletters

Stay connected with all of the latest from Drug Discovery News.

Subscribe

Sponsored

A black mosquito is shown on pink human skin against a blurred green backdrop.

Discovering deeper insights into malaria research

Malaria continues to drive urgent research worldwide, with new therapies and tools emerging to combat the parasite’s complex lifecycle and global burden.
Three burgundy round and linear conformations of oligonucleotides are shown against a black background.

Accelerating RNA therapeutic testing with liver microphysiological platforms

Researchers can now study oligonucleotide delivery and efficacy in a system that models a real human liver.
A 3D-rendered illustration of a eukaryotic cell highlighting organelles such as the nucleus, endoplasmic reticulum, mitochondria, and cytoskeletal structures in pink and purple tones.

Shining light on the subcellular proteome

Discover how innovative proteomics tools help researchers peer into once inaccessible organelles, allowing for new targets for drug discovery and development.
Drug Discovery News March 2025 Issue
Latest IssueVolume 21 • Issue 1 • March 2025

March 2025

March 2025 Issue

Explore this issue